4-[5-(3-pyridyl)-2H-tetrazol-2-yl]-phthalonitrile | 1245812-87-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[5-(3-pyridyl)-2H-tetrazol-2-yl]-phthalonitrile
• 英文别名: 4-(5-pyridin-3-yltetrazol-2-yl)benzene-1,2-dicarbonitrile
• CAS: 1245812-87-6
• 化学式: C₁₄H₇N₇
• 分子量: 273.256
• InChiKey: JYUDSQPHKWFFNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] 2, 5-DISUBSTITUTED TETRAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS DE TÉTRAZOLE 2,5-DISUBSTITUÉ ET LEUR UTILISATION COMME MODULATEURS DES RÉCEPTEURS NICOTINIQUES DE L'ACÉTYLCHOLINE
  申请人：NEUROSEARCH AS

  公开号：WO2010106106A1

  公开（公告）日：2010-09-23

  This invention relates to novel tetrazole derivatives of formula (I), which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro- degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.

  本发明涉及一种新型四唑衍生物（I）的配方，其被发现是乙酰胆碱受体的调节剂。由于它们的药理特性，本发明的化合物可能对与中枢神经系统（CNS）和周围神经系统（PNS）的胆碱能系统相关的疾病或障碍，与平滑肌收缩相关的疾病或障碍，内分泌疾病或障碍，神经退行性疾病或障碍，与炎症、疼痛和化学物质滥用终止引起的戒断症状相关的疾病或障碍的治疗可能有用。
• 2,5-DISUBSTITUTED TETRAZOLE DERIVATIVES AND THEIR USE AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS
  申请人：Dahl Bjarne H.

  公开号：US20120095056A1

  公开（公告）日：2012-04-19

  This invention relates to novel tetrazole derivatives of formula (I), which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro- degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.